Feature | April 27, 2015

New Concept of Heart Disease Posits Vitamin C Deficiency as Culprit

Study of transgenic mouse model shows chronic vitamin C deficiency leads to structural weakness of blood vessel walls, causing atherosclerotic development

April 27, 2015 — Scientific confirmation has just been published in the American Journal of Cardiovascular Disease that atherosclerosis, the underlying process of heart attacks and strokes, is generally not caused by high cholesterol blood levels. It is rather the result of a structural weakness of the blood vessel walls caused by chronic deficiency of ascorbate (vitamin C).

Heart attacks, strokes and other forms of cardiovascular disease are the single largest disease on our planet with more than 17 million deaths each year. The continuation of this disease in epidemic proportions proves that its true nature has not yet been sufficiently understood. Moreover, the current hypothesis that high cholesterol levels in blood triggers cardiovascular disease cannot answer the most basic question of cardiology: Cholesterol has the same concentration in both arteries and veins. So why do atherosclerotic plaques occur only in arteries – but not in veins? Moreover, why do they develop almost always in the few inches of coronary arteries – but rarely in other organs? Or why is atherosclerosis, a hallmark of the human race, basically unknown in animal species? 

Researchers from the Dr. Rath Research Institute in California developed a unique animal model. It is a transgenic mouse that resembles human metabolism in its key aspects, the inability to produce vitamin C and, at the same time, the synthesis of human Lipoprotein(a) – a variant of low-density-lipoprotein (LDL).  Using this animal model they demonstrated that atherosclerosis, generally, starts with a dietary depletion of vitamin C and the ensuing structural weakness of the artery walls. This metabolic condition results in an increase in serum Lipoprotein(a) levels and its accumulation in the vascular wall that parallels atherosclerotic lesion development.

This study confirms the scientific concept published in 1990 in the 'Proceedings of the National Academy of Sciences, USA' by Matthias Rath, M.D., together with two-time Nobel Prize winner Linus Pauling, M.D. They proposed that Lipoprotein(a) is a repair molecule that functions as a surrogate for vitamin C in the impaired vascular wall. 

The most fascinating aspect of this animal model is the fact that it reproduces a genetic switch, the disappearance of vitamin C to the appearance of Lipoprotein(a), from about 40 million years ago. It proves the concept that a distinct event during the evolution of man can explain the susceptibility of modern man to cardiovascular disease.

For more information: www.ajcd.us

Related Content

Videos | Cath Lab | May 20, 2019
This is a walk through of the primary structural heart hybrid cath lab at...
Mobility May Predict Elderly Heart Attack Survivors' Repeat Hospital Stays
News | Cath Lab | April 23, 2019
Determining which elderly heart attack patients take longer to stand from a seated position and walk across a room may...
FDA Releases New Guidance on Medical Devices Containing Nitinol
News | Cath Lab | April 18, 2019
April 18, 2019 — The U.S.
Angiography shows a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL lithoplasty.

Figure 2: Angiography demonstrates a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification (double-headed arrow) in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL (inset; note the cavitation bubbles generated by IVL [black arrows]). (D) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-IVL and coregistered to the OCT lens (white arrow in C) demonstrate multiple calcium fractures and large acute luminal gain. (E) Angiography demonstrates complete stent expansion with the semicompliant stent balloon (inset) without the need for high-pressure noncompliant balloon inflation. (F) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-stenting and coregistered to the OCT lens (arrow in E) demonstrate further fracture displacement (arrow), with additional increase in the acute area gain (5.17 mm2), resulting in full stent expansion and minimal malapposition.

Feature | Cath Lab | April 15, 2019 | Dean Kereiakes, M.D., FACC, FSCAI, and Jonathan Hill, M.D., DISRUPT CAD III Co-Principal Investigators
Over the last 40 years, despite multiple advancements in percutaneous coronary interventions, calcified lesions remai
BIOTRONIK’s PK Papyrus covered coronary stent. The stent ius used in emergency coronary artery dissections to repair the vessel wall.
Technology | Cath Lab | April 15, 2019
April 15, 2019 — Biotronik began its U.S.
Providing Follow-Up Care After Heart Attack Helps Reduce Readmissions, Deaths
News | Cath Lab | April 09, 2019
A program designed to help heart attack patients with the transition from hospital to outpatient care can reduce...
TherOx Receives FDA Approval for SuperSaturated Oxygen Therapy
Technology | Cath Lab | April 08, 2019
TherOx Inc. announced that the U.S. Food and Drug Administration (FDA) granted premarket approval for its...
Cook Medical Recalls Transseptal Needle Due to Risk of Detached Plastic Fragments
News | Cath Lab | March 20, 2019
March 20, 2019 — Cook Medical is recalling one lot of its...
DABRA Excimer Laser System Demonstrates Success in Treating PAD
News | Cath Lab | February 27, 2019
Ra Medical Systems Inc. announced a 98 percent success rate in the results from a 52-patient study using the company’s...
Edwards Lifesciences Recalls Swan-Ganz hemodynamic catheters.
Feature | Cath Lab | February 06, 2019
Edwards Lifesciences is recalling its 131F7, 131F7J, 131F7P, 131VF7P, 151F7 Swan-Ganz Thermodilution Catheters manufa
Overlay Init